January 20, 2017

January 20, 2017

NETTER-1 Significant Improvement in Quality of Life
OncologyTube – Jan. 20
Jonathan R. Strosberg, MD of the H. Lee Moffitt Cancer Center discusses a poster he is presenting at ASCO GI 2017 about the Significant Improvement in Quality of Life from the data of the NETTER-1 Phase III trial.

After NETTER-1 Next Steps for Neuroendocrine Tumor Research
OncologyTube – Jan. 20
Jonathan R. Strosberg, MD of the H. Lee Moffitt Cancer Center discusses what happens after NETTER-1 in Neuroendocrine Tumor research at ASCO GI 2017

NETTER-1 Phase III Trial Results Meet Primary Endppoint
OncologyTube – Jan. 20
Jonathan R. Strosberg, MD of the H. Lee Moffitt Cancer Center discusses the Phase III trial results of NETTER-1 as reported by the New England Journal of Medicine 

Dr. Strosberg on Quality of Life Findings for Lu-Dotatate in Patients with Midgut NETs
OncLive – Jan. 19
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

Mix Performers in Focus- Apricus Biosciences, Inc. (NASDAQ:APRI), Delcath Systems, Inc.
Seneca Globe – Jan. 19
The retrospective study was conducted by teams from Moffitt Cancer Center in Tampa, FL and the University of Southampton in the United Kingdom. 

Common Food Pigment May Fight Cancer
Tufts Now – Jan. 19
It’s the first time nicotine receptors on the surface of lung cells have been linked to BCX, according to Srikumar Chellappan, a cancer biologist at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida.

Rep. Castor: Here's what Obama did for Tampa Bay
Tampa Bay Times – Jan. 18
The Recovery Act created the types of jobs that helped pull us out of tough economic times. Building more new community health centers than any other region in the nation created construction and medical jobs, and opened access to thousands of more patients. Moffitt Cancer Center received a boost for construction and research that will continue with the recent adoption of the 21st Century Cures Act for the Cancer Moonshot and Brain Initiative.

Volunteers spruce up University area
Tampa Bay Times – Jan. 18
Key partners included: USF Stampede of Service, Moffitt Cancer Center, Bank of America, Red Cross, Hillsborough County Sheriff’s Office, Hillsborough County Code Enforcement, University Village, Temple Terrace Chamber of Commerce, City Councilman Luis Vierra, CANDO, Freedom High School, and the Tampa Players.

Florida DOH to present immunization summit
Tampa Bay Newspapers – Jan. 18
The summit is presented by Suwannee River Area Health Education Center; Florida Department of Health; the Partnership to Immunize Teens and Children Against HPV; the Florida Chapter of the American Academy of Pediatrics; Moffitt Cancer Center; the Pinellas Immunization Team for Community Health and the National AHEC Organization HPV Immunization Project. 

New Outcomes Data Using Delcath’s Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium
Military Technologies – Jan. 18
The retrospective study was conducted by teams from Moffitt Cancer Center in Tampa, FL and the University of Southampton in the United Kingdom. 
Also seen on KUSI, WVUE, WTVM, KTIV, WIS, WVIR, KFVS, WOIO, KHQ, Ariva, KQCW, KAUZ, KOTV, WBND, WOWK, KWTV, WUPVWTOC, KXXV, WBRC, WLBT, WDJT, KMOV, WTOL, WMBF, WBTV, KWES, KFXG, WOHL, KSWO, KOAM, AZ Family, KTRE, KWWL, WLTZ

Vaccine shows promise for early-stage HER2-positive breast cancer
Modern Medicine – Jan. 18
A dendritic cell vaccine that targets HER2 protein may induce an immune response leading to regression of early-stage breast tumors, according to results of research from the Moffitt Cancer Center published in Clinical Cancer Research.
Also seen at Contemporary OBGYN.

Ruckdeschel Takes Lead Role in UMMC’s Cancer Fight
Ole Miss News – Jan. 18
Ruckdeschel, who previously served as the director of the Moffitt Cancer Center in Tampa, Florida, led that institution to National Cancer Institute Comprehensive Cancer Center designation and to become the third-largest clinical cancer program in the United States.

New drug in development shows improved progression-free survival for patients with advanced metastatic midgut neuroendocrine tumors
eCancer News – Jan. 18
“Patients diagnosed with midgut neuroendocrine tumours often have advanced disease that has spread to other sites. Treatment options are limited. 177Lu-Dotatate is an effective option to delay tumour progression for patients with this disease,” says Jonathan R. Strosberg, head of the Neuroendocrine Tumor Program at Moffitt Cancer Center. 

Kura Oncology (KURA) Begins Dosing in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
Street Insider – Jan. 17
“New pharmaceutical treatments are urgently needed to combat this rare disease,” said Eric Padron, M.D., of the Department of Hematologic Malignancies at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, a clinical investigator on this study. 
Also seen at PublicNow.com, The Arizona Republic, 4Traders.com, BioSpace.com and Pharmiweb.com

National Association For Business Resources Recognizes Moffitt Cancer Center
Tampa Patch – Jan. 17
Moffitt Cancer Center is a two-time Best and Brightest winner recognized by the National Association for Business Resources. The cancer center has been named one of the Best and Brightest Companies To Work For®, as well as one of the Best and Brightest Companies in Wellness.

St. Luke’s surgeons first in state to use innovative pancreatic cancer treatment
Milwaukee Business Times – Jan. 17
The procedure was first introduced more than a decade ago at several cancer centers around the country, including the Moffitt Cancer Center in Tampa, Florida; The Cleveland Clinic in Ohio; and the Memorial Sloan Cancer Center in New York.

Protein-Inhibiting Therapy May Reduce Stem-cell Transplant Complication GVHD
Lymphoma News Today - Jan. 16
In an attempt to develop better treatments to prevent GVHD, without affecting the patient’s ability to fight infections or tumor cells, researchers at the Moffitt Cancer Center focused on the proteins Aurora A and JAK2.

Quality of Life in Transfusion-Dependent MDS
OncLive - Jan. 16
Rami S. Komrokji, MD: Finally, I think we are getting into more objective tools to assess quality of life. There are now quality-of-life tools that are specific for MDS that are starting to be incorporated. 

MOFFITT RESEARCHERS DEVELOPING VACCINE TO FIGHT BREAST CANCER
WUSF – Jan. 16
Researchers at Tampa’s Moffitt Cancer Center are testing a vaccine to fight breast cancer, and they say that it appears to be working for some patients.
Also appeared at WMFE.org.

Vaccine Shows Benefit in Early-Stage Breast Cancer
Cure – Jan. 13
In an interview with CURE, Czerniecki, chair, Department of Breast Oncology, Moffitt Cancer Center, discussed the significant findings of this trial and the importance of developing cancer vaccines.

HER2 Vaccine Safe, Immunogenic in Early-Stage Breast Cancer
Targeted Oncology – Jan. 13
In an interview with OncLive, Czerniecki, chair, Department of Breast Oncology, Moffitt Cancer Center, discussed the significant findings of this trial and the importance of developing cancer vaccines.

Moffitt Researchers Developing Vaccine To Fight Breast Cancer
WUSF – Jan. 13
Researchers at Tampa's Moffitt Cancer Center are testing a vaccine to fight breast cancer,  and they say  that it appears to be working for some patients.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.